Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency discusses potential bolus of applications in new fiscal year.


Related Content

FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts